Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Some patients use semaglutide for defined periods to achieve target weights, then taper or discontinue
Nothing on this part of the website, nor anything which can be downloaded from it, constitutes an offer for sale or subscription or any solicitation for any offer to purchase or subscribe for any securities (or solicitation of any votes attaching to securities which are the subject of the Offer) in any jurisdiction in which such offer or solicitation is unlawful
The robust weight loss combined with a well-tolerated safety profile reinforces our confidence in the clinical development programme [of CT-388] as we advance to phase III trials" Dr Levi Garraway, PhD, Roches Chief Medical Officer and Head of Global Product Development, said: We are pleased to see such meaningful weight loss in people treated with CT-388
The drug remains in active clinical development, with Phase 3 trials currently underway evaluating retatrutide's efficacy and safety across broader populations, including individuals with obesity, type 2 diabetes, and cardiovascular disease
US$ 23.94
US$ 29.50
US$ 20.02
